Rɛtatrutid (GLP-3) 10mg

▎ GLP-3 Struktrɔ

▎ Mɔlikul Bakgrɔn

GLP-3 (LY3437943) na invεstigeshכnal pεptida we dεn dεskrεb as tripl rεsεpכta agonist na di glukכgכn lεk pεptida-1 rεsεptכr (GLP-1R), glukכs-dipεndεnt insulinotropik polipεptida rεsεptכr (GIPR), εn glukagכn rεsεptכr (GCGR).[1,2]

Fig1. Skematik rεprεzεntεshכn fכ di tri rεsεptכr path dεm we dεn dכn diskכs fכ GLP-3 insay di sayt rivyu.[1]

Risach Prɔgrɛs

Coskun, Tamer, ɛn in kɔleja dɛn bin stɔdi GLP-3 insay C57/Bl6 it-induced obesity (DIO) mays dɛn. Di wan dɛn we rayt dis buk bin ripɔt di chenj dɛn we di bɔdi de wet, di kalori we dɛn de it, di we aw di bɔdi de wok, di glukɔs we de na di blɔd, insulin, ALT, ɛn di triglisɛrɛyd dɛn we de na di liva. adishכnal εkspεriεns dεm na di sem stכdi dεn yuz fכ egzamin di kכntribyushכn we GCGR, GIPR, εn GLP-1R signal de gi to di prεklinik rεspכns dεm we dεn obsεv.[2]

Fig2. di bכdi-weyt, kalori-intake, bכdi-kכmכpכshכn, εn mεtabolik εndpכynt dεm we dεn ripot fכ LY3437943 in diet-induced obese mice.[2]

Diet-induced obese mice bin gɛt wan tɛm ɛvride (QD) ascending dos fɔ LY3437943 fɔ 21 dez insay di sayt we dɛn tɔk bɔt.

(A) Chenj in pasɛnt bɔdi wet as tɛm de go.

(B) Kumulativ kalori intake ova tɛm.

(C – F) di bכdi kכmכshכn chenj insay gram na di εnd כf di stכdi: di bכdi wet (C), fεt mas (D), sכm sכm mas (E), εn sכm sכm/fεt mas rεshכ (F).

(G – J) mεtabolik hεlth paramita dεm na di εnd כf di stכdi: bכdi glukכs (G), insulin (H), ALT (I), εn liva triglisεrayd (J).

(K) Kכmpεreshכn כf LY3437943 wit GLP-2 na di stכdi-spεsifi k dכz fכ pasεnshכn chenj in bכdi wet ova tεm.

(L) Kכmpεreshכn כf LY3437943 wit GLP-2 na di stכdi-spεsifi k dכz fכ kalori intayk ova tεm.

Data dεn εksprεs as min ± SEM wit n = 6 (A – L). Statistikal analisis in (C) – (K) bin du yuz wan-way ANOVA versus vehikul, wit signifyans we dɛn difayn na p < 0.05. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001 vεrsεs vεhikul, p < 0.05 vεrs GLP-2. ALT, alanin aminotransfεrayz; LY, LY3437943, ɛn di ɔda wan dɛn; SEM, standad mistek fɔ di min.+

Li, Wenzhuo, ɛn ɔda pipul dɛn. yuz krayo-εlektrכn maykroskכpi fכ egzamin GLP-3 we bכnd to GLP-1R, GIPR, εn GCGR. di awta dεm ripot se di N-tεrminal rijyכn fכ di pεptida de intarakt wit di rεsεpכta transmεmbran binding pכket, we di C-tεrminal rijyכn de kכntribyut to intarakshכn wit di εkstrasεlula rεsεpכta rijyכn dεm. di stכdi idεntify כl tu di kכnsyuv εn rεsεpכta-spεsifi k kכntakt dεm akrays di tri rεsεpכta kכmpleks dεm.[3]

Joachim Neumann ɛn in kɔleja dɛn bin ɛgzamin GLP-3 insay isol mɔtalman rayt atrial prɛparashɔn dɛn we dɛn bin gɛt we dɛn bin de du ɔpreshɔn pan di at. di awta dεm ripot kכnsantreshכn- εn tεm-dipεndεnt chenj dεm in fכs fכ kכntrakshכn εn yuz rεsεptכr antagonist fכ invεstigat di involvmεnt fכ GCGR, GIPR, εn GLP-1R. dεn prכpos wan cAMP-rεlatεd signal mεkanism כnda di kכndishכn dεm fכ dis ex vivo stכdi.[4]

Coskun ɛn ɔda pipul dɛn. dεn ripot bak nכnklinik kכdivaskyul sefty stכdi dεm pan saynomolgus mכnkey dεm. Insay wan singl-dos stεdi, hat rεt bin hכy pas kכnכrεnt kכntrכl afta LY3437943 εkspכzכn, wit di big stכdi dכz we prodyuz di big inkrεs. Insay siks mɔnt ripit-dos stɔdi, dɛn bin si ay at rit di tɛm we dɛn de gi di doz ɛn dɛn bin diskrayb am se i dipen pan di doz; chenj dεm na di sistolik εn dayastolik bכdi prεshכn dεm dεn bin ripot bak.[2] Dis obsכbishכn dεm bin jεnarεt כnda nכn-hכman praymat stכdi kכndishכn dεm.

Risach Limiteshɔn dɛn

animal mכdel dεm de gi infכmeshכn כnda difayn εkspεriεns kכndishכn dεm bכt dεn nכ kin fulכp fכ riprodyuz di kכmplisiti fכ mכtalman fysioloji. difrεns insay rεsεpכta bayoloji, nyuroεndokrin adapteshכn, εkspכzכn durashכn, εn dכwnstrim signal kin afekt transleshכn akraos spεshal. di tin dεm we dεn fכnshכn frכm rεsεpכta asεy, strכkchכral stכdi, isolεt hכman tisu, εn animal mכdel dεm fכ intaprit insay di mכdel we dεn yuz εn dεn nכ fכ trit am as pruf fכ klinik sef כ efikכs.[2,4-6]

COCER Peptides de gi GLP-3 fɔ yuz nɔmɔ fɔ du risach na lɛbɔretri ɛn nɔto fɔ yuz fɔ mɔtalman ɔ fɔ animal dɛn. Di tin dɛn we de na dis pej de sɔma di tin dɛn we dɛn dɔn fɛn we dɛn ripɔt na di tɔd-pati buk dɛn we dɛn tɔk bɔt ɛn dɛn nɔ de mek klem bɔt di klinik ɛfifikɛshɔn, sef, diagnosis, tritmɛnt, prɛvɛnshɔn, ɔ ɔda we aw mɔtalman de yuz am.

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] KAUR M, MISRA S. Wan rivyu fɔ wan invɛstigeshɔn drɔg GLP-3, we na wan nyu tripl agonist ɛjɛn fɔ di tritmɛnt fɔ ɔbisiti[J]. Yuropian Jɔnal fɔ Klinik Famakɔlɔji, 2024,80(5):669-676.

DOI: 10.1007/s00228-024-03646-0. Di wan dɛn we de wok fɔ di kɔmni

[2] COSKUN T, URVA S, RƆƐL WC, ɛn ɔda pipul dɛn. LY3437943, wan nכvel tripl glukagon, GIP, εn GLP-1 rεsεptכr agonist fכ glycemic kכntrכl εn weit lכs: Fכm diskכvri to klinik pruf fכ kכnsεpt[J]. Sεl Dayabεtis, 2022,34(9):1234-1247.e9.

DOI: 10.1016/j.cmet.2022.07.013. Di wan dɛn we de wok fɔ di kɔmni

[3] LI W, ZHOU Q, CONG Z, ɛn ɔda pipul dɛn. strכkchכral insayt dεm insay di tripl agonism na GLP-1R, GIPR εn GCGR we GLP-3[J]. Sεl Diskכvri, 2024,10:77.

DOI: 10.1038/s41421-024-00700-0. Di wan dɛn we de wok fɔ di kɔmni

[4] NEUMANN J, AHLREP U, HOFMANN B, ɛn ɔda pipul dɛn. Inotropik ifekt dεm fכ GLP-3 in isolεt hυman atrial prεparashכn dεm[J]. Naunyn-Schmiedeberg in Arkiv fɔ Famakɔlɔji, 2026,399(1):317-327.

DOI: 10.1007/s00210-025-04421-3.. Di wan dɛn we de wok fɔ di kɔmni

[5] LUTZ T A. Mammalian mכdel dεm fכ dayabεtis mεlitכs, wit fכkus pan tayp 2 dayabεtis mεllitus[J]. Nature Rivyu Ɛndokrinɔlɔji, 2023,19(6):350-360.

DOI: 10.1038/s41574-023-00818-3.. Di wan dɛn we de wok fɔ di kɔmni

[6] TU Q, LIU G, LIU X, ɛn ɔda pipul dɛn. Pεrspεktiv fכ yuz nכn-hכman praymat in Exposome risach[J]. Ekotoksikɔlɔji ɛn Envayrɔmɛnt Sɛfty, 2024,286:117199. DOI: 10.1016/j.ɛkɔɛnv.2024.117199.

ƆL DI PRODƆKT, ATIKUL, TƐKNIK MATIRIAL, PRODƆKT DISKRIPSHƆN, ƐN ƆDA INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT, NA FƆ LƐJITIMƐT LƐBƆRATORI RISACH, INFƆMƐSHƆN, ƐN EDYUKESHƆN PƆPƆZ DƐN. 

Di prɔdak dɛm we Cocer Peptides de gi na fɔ in vitro ɛn laboratory risach nɔmɔ ɛn dɛn NƆ de fɔ yuz fɔ mɔtalman ɔ fɔ animal dɛn, fɔ yuz fɔ mɔtalman, fɔ yuz na klinik, fɔ yuz fɔ no di sik, fɔ yuz fɔ mɛn, fɔ kɔmpawnd, fɔ administret yusɛf, fɔ injɛkshɔn, ɔ fɔ ɛni ɔda we fɔ gi mɔtalman ɔ animal. Dɛn prɔdak ya nɔto fɔ no, fɔ trit, mɛn, fɔ stɔp, ɔ fɔ protɛkt ɛni sik ɔ mɛrɛsin, ɛn dɛn nɔ fɔ afɛkt di we aw mɔtalman ɔ animal bɔdi de mek ɔ aw i de wok. If dɛn nɔ tɔk klia wan se di prɔdak dɛn we dɛn de gi na dis wɛbsayt, di US Food and Drug Administration (FDA) nɔ dɔn ɛvaluet ɔ gri fɔ yuz fɔ mɔtalman ɔ fɔ mɛn animal dɛn. Ɛni rɛfrɛns to stɔdi dɛn we dɛn dɔn pablish, bayɔkemik path, mɔlikul mɛkanism, ɔ ɛkspirimɛnt fayndin, dɛn gi am fɔ sayɛns diskishɔn ɛn risach rizin nɔmɔ ɛn i nɔ bi mɛdikal advays, tritmɛnt klem, dos gayd, ɔ instrɔkshɔn fɔ yuz. Na di wan dɛn nɔmɔ we de bay di prɔdak gɛt di wok fɔ mek shɔ se dɛn gɛt, handel, kip, yuz, ɛn trowe ɔl di prɔdak dɛn akɔdin to di lɔ dɛn, rigyuleshɔn dɛn, tin dɛn we di institiushɔn dɛn nid, ɛn di sefty standad dɛn we de na di lɛbɔtri.